secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001493152-24-043130
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.05, 2.06, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma terminates MAT2203 partnership, cuts 80% workforce, ceases development, considers dissolution
--------------------------------------------------------------------------------

- Partnership negotiations for MAT2203 global rights terminated; prospective partner withdrew.
- 80% workforce reduction of 15 positions, including CMO, CBO, and CTO, effective Oct 31, 2024.
- All product development ceased; exploring asset sale of MAT2203 or winddown/dissolution of the company.
- CMO James Ferguson terminated; severance ~$500k (12 months base salary plus benefits).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224043130/0001493152-24-043130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224043130/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer